Natera, Inc. $NTRA Stock Position Decreased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 12.8% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 2,044,534 shares of the medical research company’s stock after selling 300,076 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Natera were worth $345,404,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Edgestream Partners L.P. acquired a new stake in shares of Natera in the 1st quarter valued at $1,187,000. Apollon Wealth Management LLC raised its holdings in Natera by 26.2% during the first quarter. Apollon Wealth Management LLC now owns 2,959 shares of the medical research company’s stock valued at $418,000 after buying an additional 614 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Natera by 20.8% in the first quarter. Victory Capital Management Inc. now owns 423,204 shares of the medical research company’s stock worth $59,845,000 after buying an additional 73,003 shares during the last quarter. Diversify Advisory Services LLC bought a new stake in shares of Natera during the 1st quarter worth about $254,000. Finally, Allianz Asset Management GmbH increased its holdings in shares of Natera by 179.2% during the 1st quarter. Allianz Asset Management GmbH now owns 251,883 shares of the medical research company’s stock valued at $35,619,000 after acquiring an additional 161,672 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Evercore ISI boosted their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. BTIG Research lifted their price target on shares of Natera from $210.00 to $230.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Stephens upped their price objective on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. Fifteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $216.65.

Natera Price Performance

NASDAQ NTRA opened at $204.28 on Friday. The company’s fifty day moving average is $181.51 and its two-hundred day moving average is $165.65. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $212.21. The firm has a market capitalization of $28.19 billion, a price-to-earnings ratio of -89.21 and a beta of 1.75.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period in the prior year, the company posted ($0.26) EPS. The firm’s quarterly revenue was up 34.7% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the sale, the director owned 6,015 shares in the company, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total value of $479,970.00. Following the sale, the insider directly owned 117,559 shares in the company, valued at $18,808,264.41. The trade was a 2.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 223,336 shares of company stock worth $42,990,633. Insiders own 5.63% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.